Am J Psychiatry 1987; 144:1148-1153
Copyright © 1987 by American Psychiatric Association

REGULAR ARTICLES

Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study

PJ Weiden, JJ Mann, G Haas, M Mattson and A Frances

Extrapyramidal side effects are a major limitation in the use of neuroleptics, and tardive dyskinesia is a special public health problem. Accurate clinical diagnosis of extrapyramidal syndromes is necessary for effective management. The authors compared clinicians' recognition of the major extrapyramidal syndromes in 48 psychotic inpatients with independent blind diagnoses by clinical researchers using standardized ratings. The major finding was a high rate of clinical underrecognition of all major extrapyramidal syndromes, especially tardive dyskinesia. The authors discuss the clinical predictors of nonrecognition of extrapyramidal side effects and recommend improved training in their detection.

This article has been cited by other articles:

				D. C. Owens How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia Advan. Psychiatr. Treat., January 1, 2008; 14(1): 17 - 28. [Abstract] [Full Text] [PDF]

				K. L. Claxton, J. J. Chen, and D. M. Swope Drug-Induced Movement Disorders Journal of Pharmacy Practice, December 1, 2007; 20(6): 415 - 429. [Abstract] [PDF]

				P. J. Weiden Switching antipsychotics: an updated review with a focus on quetiapine J Psychopharmacol, January 1, 2006; 20(1): 104 - 118. [Abstract] [PDF]

				J. H. Friedman, H. H. Fernandez, and M. M. Trieschmann Parkinsonism in a Nursing Home: Underrecognition J Geriatr Psychiatry Neurol, March 1, 2004; 17(1): 39 - 41. [Abstract] [PDF]

				T. R. E. Barnes The Barnes Akathisia Rating Scale-Revisited J Psychopharmacol, December 1, 2003; 17(4): 365 - 370. [Abstract] [PDF]

				J. H. Friedman, R. Skeete, and H. H. Fernandez Letters to the Editor: Unrecognized Parkinsonism In Acute Care Medical Patients Receiving Neurological Consultations J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2003; 58(1): M94 - 95. [Full Text] [PDF]

				D. G. Daniel Recent Developments in Pharmacotherapy for the Acutely Psychotic Patient Journal of the American Psychiatric Nurses Association, December 1, 2002; 8(6_suppl): S40 - S47. [PDF]

				H. Akagi and T M. Kumar Lesson of the week: Akathisia: overlooked at a cost BMJ, June 22, 2002; 324(7352): 1506 - 1507. [Full Text] [PDF]

				K. P. Bailey Pharmacologic Agents for the Treatment of Schizophrenia: Similarities and Differences Journal of the American Psychiatric Nurses Association, October 1, 1996; 2(5): 181 - 185. [Abstract] [PDF]

				S. A Lynn and R. D Plant Dyskinesia in chronic schizophrenia: an examination of the psychiatric nurse's perspective and its implications for physiotherapy Clinical Rehabilitation, May 1, 1995; 9(2): 97 - 101. [Abstract] [PDF]

				T. R. E. Barnes Clinical assessment of the extrapyramidal side effects of antipsychotic drugs J Psychopharmacol, January 1, 1992; 6(2): 214 - 221. [PDF]

				D. S. Sherman Psychoactive Drug Misuse in Long-Term Care: Some Contributing Factors Journal of Pharmacy Practice, December 1, 1988; 1(3): 189 - 194. [Abstract] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 1987 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us